Показано 0 из 0
Дата |
---|
17.05.2024 |
16.05.2024 |
15.05.2024 |
14.05.2024 |
13.05.2024 |
10.05.2024 |
09.05.2024 |
08.05.2024 |
07.05.2024 |
06.05.2024 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
---|---|---|---|---|---|---|---|
4.41
|
5.33
|
5.00
|
4.4872
|
5.06
|
4.4872
|
|
|
33 848.07
|
126.00
|
4.78
|
5.15
|
4.94
|
4.84
|
4.94
|
4.84
|
|
|
5 791.94
|
57.00
|
4.81
|
5.62
|
5.34
|
4.87
|
5.34
|
4.90
|
|
|
22 527.45
|
68.00
|
5.23
|
5.79
|
5.36
|
5.29
|
5.41
|
5.29
|
|
|
22 124.13
|
52.00
|
5.27
|
5.81
|
5.21
|
5.21
|
5.47
|
5.47
|
|
|
27 660.19
|
83.00
|
5.16
|
5.69
|
5.28
|
5.20
|
5.39
|
5.2287
|
|
|
19 986.56
|
144.00
|
5.17
|
5.38
|
5.52
|
5.10
|
5.62
|
5.27
|
|
|
79 390.51
|
539.00
|
5.50
|
5.69
|
6.32
|
5.50
|
6.40
|
5.60
|
|
|
82 942.81
|
902.00
|
6.25
|
6.30
|
6.15
|
6.06
|
6.65
|
6.41
|
|
|
68 733.92
|
125.00
|
6.22
|
6.34
|
5.80
|
5.80
|
6.55
|
6.3899
|
|
|
199 223.19
|
476.00
|
ZyVersa is a clinical stage specialty biopharmaceutical company leveraging advanced proprietary technologies to develop first-in-class drugs for patients with inflammatory or kidney diseases with high unmet medical needs.